Immune & Antimicrobial

Thymopentin

Last updated 12 August 2026

Evidence on file7 human observational studies · 1 human case report or series · 2 citations not yet graded

Strongest sourceEfficacy and safety of thymosin combined with anticancer therapy for esophageal cancer: a systematic review a… (human observational study)

Dosing on file unverified

SC: 50 mg 3x/week (HIV); IV: 50 mg 3x/week (RA); SC: 10 mg daily then 3x/week (PD)

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 10

human observational
Efficacy and safety of thymosin combined with anticancer therapy for esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. graded on: a synthesis of human studies — “systematic review”
human observational
Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study. graded on: an observational human design — “retrospective”
human case series
Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance. graded on: a case report or series — “Case Report”
human observational
NCT00002109: Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy graded on: a registered clinical study — “clinicaltrials.gov”
human observational
NCT00460681: Phase III Study of Thymopentin in Patients After Curative Resection of Small graded on: a registered clinical study — “clinicaltrials.gov”
human observational
NCT00002332: Double-Blind Study of the Effect of Timunox (Thymopentin) on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Antiretroviral Therapy graded on: a registered clinical study — “clinicaltrials.gov”
human observational
NCT06112041: The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors(PRaG9.0) graded on: a registered clinical study — “clinicaltrials.gov”
human observational
NCT00002049: Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients graded on: a registered clinical study — “clinicaltrials.gov”

Not graded

2 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

not graded
Thymopentin (1986)
not graded
Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8+ T cells.

Identity

Space-filling 3D model of Thymopentin, carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of Thymopentin — Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 679.8
Molecular formula: C30H49N9O9
CAS number: 69558-55-0
PubChem CID: 451417
InChI key: PSWFFKRAVBDQEG-YGQNSOCVSA-N
Sequence: RKDVY
SMILES: CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N
InChI: InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1

Notes unverified prose

Human trials: 50 mg SC 3x/week; 50 mg IV 3x/week; 10 mg SC daily; 1 mg/kg SC; Approved in some countries; 50 mg SC 3x/week

Not on file 0

All 8 tracked fields hold a value on this record: molecular weight and formula, CAS number, PubChem CID, amino-acid sequence, SMILES, InChI and InChI key.

Counted from the record itself, not from what a source said it was missing. 136 of 185 records still have at least one empty.